Distribution of andrological diagnoses in male patients managed during COVID period and pre-COVID period
| Study Parameters . | Pre-COVID period (n = 3,231) . | COVID period (n = 1724) . | P . |
|---|---|---|---|
| Andrological diseases, n (%) | 428 (13.2%) | 293 (17%) | <0.001 |
| Male reproductive health diseases, n (%) | 149 (4.6%) | 107 (6.2%) | 0.016 |
| Male sexual health diseases, n (%) | 279 (8.6%) | 186 (10.8%) | 0.013 |
| Erectile dysfunction, n (%) | 214 (6.6%) | 150 (8.7%) | 0.008 |
| Erectile dysfunction, Age, mean ± SD | 49.4 ± 12.9 | 45.3 ± 12.6 | 0.003 |
| Varicocele, n (%) | 86 (2.7%) | 69 (4%) | 0.010 |
| Infertility, n (%) | 45 (1.4%) | 33 (1.9%) | 0.160 |
| Premature ejaculation, n (%) | 46 (1.4%) | 25 (1.5%) | 0.941 |
| Peyronie's disease, n (%) | 36 (1.1%) | 16 (0.9%) | 0.540 |
| Study Parameters . | Pre-COVID period (n = 3,231) . | COVID period (n = 1724) . | P . |
|---|---|---|---|
| Andrological diseases, n (%) | 428 (13.2%) | 293 (17%) | <0.001 |
| Male reproductive health diseases, n (%) | 149 (4.6%) | 107 (6.2%) | 0.016 |
| Male sexual health diseases, n (%) | 279 (8.6%) | 186 (10.8%) | 0.013 |
| Erectile dysfunction, n (%) | 214 (6.6%) | 150 (8.7%) | 0.008 |
| Erectile dysfunction, Age, mean ± SD | 49.4 ± 12.9 | 45.3 ± 12.6 | 0.003 |
| Varicocele, n (%) | 86 (2.7%) | 69 (4%) | 0.010 |
| Infertility, n (%) | 45 (1.4%) | 33 (1.9%) | 0.160 |
| Premature ejaculation, n (%) | 46 (1.4%) | 25 (1.5%) | 0.941 |
| Peyronie's disease, n (%) | 36 (1.1%) | 16 (0.9%) | 0.540 |
COVID = coronavirus disease 2019 pandemic period group; pre-COVID = pre–coronavirus disease 2019 pandemic period group. Bold values indicate statistical significant.
Bold values indicate statistical significant.
Distribution of andrological diagnoses in male patients managed during COVID period and pre-COVID period
| Study Parameters . | Pre-COVID period (n = 3,231) . | COVID period (n = 1724) . | P . |
|---|---|---|---|
| Andrological diseases, n (%) | 428 (13.2%) | 293 (17%) | <0.001 |
| Male reproductive health diseases, n (%) | 149 (4.6%) | 107 (6.2%) | 0.016 |
| Male sexual health diseases, n (%) | 279 (8.6%) | 186 (10.8%) | 0.013 |
| Erectile dysfunction, n (%) | 214 (6.6%) | 150 (8.7%) | 0.008 |
| Erectile dysfunction, Age, mean ± SD | 49.4 ± 12.9 | 45.3 ± 12.6 | 0.003 |
| Varicocele, n (%) | 86 (2.7%) | 69 (4%) | 0.010 |
| Infertility, n (%) | 45 (1.4%) | 33 (1.9%) | 0.160 |
| Premature ejaculation, n (%) | 46 (1.4%) | 25 (1.5%) | 0.941 |
| Peyronie's disease, n (%) | 36 (1.1%) | 16 (0.9%) | 0.540 |
| Study Parameters . | Pre-COVID period (n = 3,231) . | COVID period (n = 1724) . | P . |
|---|---|---|---|
| Andrological diseases, n (%) | 428 (13.2%) | 293 (17%) | <0.001 |
| Male reproductive health diseases, n (%) | 149 (4.6%) | 107 (6.2%) | 0.016 |
| Male sexual health diseases, n (%) | 279 (8.6%) | 186 (10.8%) | 0.013 |
| Erectile dysfunction, n (%) | 214 (6.6%) | 150 (8.7%) | 0.008 |
| Erectile dysfunction, Age, mean ± SD | 49.4 ± 12.9 | 45.3 ± 12.6 | 0.003 |
| Varicocele, n (%) | 86 (2.7%) | 69 (4%) | 0.010 |
| Infertility, n (%) | 45 (1.4%) | 33 (1.9%) | 0.160 |
| Premature ejaculation, n (%) | 46 (1.4%) | 25 (1.5%) | 0.941 |
| Peyronie's disease, n (%) | 36 (1.1%) | 16 (0.9%) | 0.540 |
COVID = coronavirus disease 2019 pandemic period group; pre-COVID = pre–coronavirus disease 2019 pandemic period group. Bold values indicate statistical significant.
Bold values indicate statistical significant.
This PDF is available to Subscribers Only
View Article Abstract & Purchase OptionsFor full access to this pdf, sign in to an existing account, or purchase an annual subscription.
